Michael Landsittel - 28 Mar 2024 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Signature
/s/ Melissa Masse, Attorney-in-Fact
Issuer symbol
BPMC
Transactions as of
28 Mar 2024
Net transactions value
-$294,750
Form type
4
Filing time
01 Apr 2024, 16:34:52 UTC
Previous filing
19 Mar 2024
Next filing
06 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $180,250 +5,000 +11% $36.05 52,286 28 Mar 2024 Direct F1
transaction BPMC Common Stock Sale $475,000 -5,000 -9.6% $95.00 47,286 28 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -5,000 -33% $0.000000 10,000 28 Mar 2024 Common Stock 5,000 $36.05 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 This option was granted on February 16, 2017 and is fully vested as of the transaction date.